NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market

NeoGenomics Inc. (NASDAQ:NEO) is one of the most buzzing stocks to buy with the highest upside potential. On February 25, NeoGenomics officially launched RaDaR ST, a tumor-informed circulating tumor DNA/ctDNA assay designed to detect molecular residual disease/MRD across various solid tumor types. This launch targets a rapidly growing MRD market estimated at over $20 billion, which NeoGenomics believes is currently less than 10% penetrated. By providing patient-specific molecular insights, the test allows clinicians to identify residual disease and recurrence earlier than traditional imaging, facilitating more timely treatment interventions.

The RaDaR ST assay uses whole-exome sequencing and advanced bioinformatics to track up to 48 tumor-specific variants. It features a high level of sensitivity, with a limit of detection at 95% probability of 11 parts per million/ppm, ensuring the identification of trace amounts of tumor DNA. The test has been validated through clinical and real-world data in several areas, including breast and head & neck cancers, and has already received Medicare approval for its initial launch indications.

NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market

Photo by RDNE on Pexels

With the introduction of RaDaR ST, NeoGenomics Inc. (NASDAQ:NEO) expands its oncology portfolio to cover the full continuum of cancer care, from initial diagnostic profiling to long-term surveillance. The CEO noted that this advancement reflects the company’s commitment to precision medicine and its investment in technologies that address unmet clinical needs.

NeoGenomics Inc. (NASDAQ:NEO) operates a network of cancer-focused testing laboratories in the US and the UK. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

While we acknowledge the risk and potential of NEO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NEO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.